Identification of a novel set of biomarkers for evaluating phospholipidosis-inducing potential of compounds using rat liver microarray data measured 24-h after single dose administration

Toxicology

Volumn 295, Issue 1-3, 2012, Pages 1-7

  Yudate, Henrik T ^a   Kai, Toshihiro ^a   Aoki, Mikio ^a   Minowa, Yohsuke ^b   Yamada, Toru ^a   Kimura, Toru ^a   Ono, Atsushi ^c   Yamada, Hiroshi ^b   Ohno, Yasuo ^c   Urushidani, Tetsuro ^b,d  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

Biomarker; Gene expression; Liver; Microarray; Phospholipidosis; Toxicogenomics

Indexed keywords

AMIODARONE; AZATHIOPRINE; BENZIODARONE; BIOLOGICAL MARKER; CEFALOTIN; CIMETIDINE; CLOFIBRATE; CLOMIPRAMINE; COLCHICINE; CYCLOSPORIN A; DANAZOL; DILTIAZEM; DISOPYRAMIDE; ENALAPRIL; FAMOTIDINE; GLIBENCLAMIDE; HALOPERIDOL; HYDROXYZINE; IBUPROFEN; IMIPRAMINE; MEFENAMIC ACID; METFORMIN; OMEPRAZOLE; PERHEXILINE; PHENYTOIN; PHOSPHOLIPID; QUINIDINE; RIFAMPICIN; TRANSCRIPTOME; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHIP; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE PROBE; GENETIC ALGORITHM; GENETIC DATABASE; HISTOPATHOLOGY; LIPID METABOLISM; LIPIDOSIS; LIVER; LIVER TOXICITY; MALE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; SPRAGUE DAWLEY RAT; TISSUE MICROARRAY;

RATTUS;

ANIMALS; BIOLOGICAL MARKERS; LIPIDOSES; LIVER; MALE; PHOSPHOLIPIDS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE ARRAY ANALYSIS;

EID: 84861181290     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.02.015     Document Type: Article

References (30)

1. Anderson N., Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006, 580:5533-5540.
2. Atienzar F., Gerets H., Dufrane S., Tilmant K., Cornet M., Dhalluin S., Ruty B., Rose G., Canning M. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol. Sci. 2007, 96:101-114.
3. Baronas E.T., Lee J.W., Alden C., Hsieh F.Y. Biomarkers to monitor drug-induced phospholipidosis. Toxicol. Appl. Pharmacol. 2007, 218:72-78.
4. Berridge B.R., Chatman L.A., Odin M., Schultze A.E., Losco P.E., Meehan J.T., Peters T., Vonderfecht S.L. Phospholipidosis in nonclinical toxicity studies. Toxicol. Pathol. 2007, 35:325.
5. Blomme E.A., Yang Y., Waring J.F. Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol. Lett. 2009, 186:22-31.
6. Carstensen B. Age-period-cohort models for the Lexis diagram. Stat. Med. 2007, 26:3018-3045.
7. Chiang A.P., Butte A.J. Data-driven methods to discover molecular determinants of serious adverse drug events. Clin. Pharmacol. Ther. 2009, 85:259-268.
8. Delaney J., Neville W.A., Swain A., Miles A., Leonard M.S., Waterfield C.J. Phenylacetylglycine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model. Biomarkers 2004, 9:271-290.
9. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22:151-185.
10. Fujimura H., Dekura E., Kurabe M., Shimazu N., Koitabashi M., Toriumi W. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development. Exp. Toxicol. Pathol. 2007, 58:375-382.
11. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
12. Gonzalez-Rothi R.J., Zander D.S., Ros P.R. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest 1995, 107:1763-1765.
13. Halliwell W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 1997, 25:53-60.
14. Hirode M., Ono A., Miyagishima T., Nagao T., Ohno Y., Urushidani T. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol. Appl. Pharmacol. 2008, 229:290-299.
15. Hruban Z. Pulmonary and generalized lysosomal storage induced by amphiphilic drugs. Environ. Health Perspect. 1984, 55:53-76.
16. Kasahara T., Tomita K., Murano H., Harada T., Tsubakimoto K., Ogihara T., Ohnishi S., Kakinuma C. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci. 2006, 90:133-141.
17. Kruhlak N.L., Choi S.S., Contrera J.F., Weaver J.L., Willard J.M., Hastings K.L., Sancilio L.F. Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicol. Mech. Methods 2008, 18:217-227.
18. Kuroda Y., Saito M. Prediction of phospholipidosis-inducing potential of drugs by in vitro biochemical and physicochemical assays followed by multivariate analysis. Toxicol. In Vitro 2010, 24:661-668.
19. Nioi P., Perry B.K., Wang E.J., Gu Y.Z., Snyder R.D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol. Sci. 2007, 99:162-173.
20. Pelletier D.J., Gehlhaar D., Tilloy-Ellul A., Johnson T.O., Greene N. Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential. J. Chem. Inf. Model. 2007, 47:1196-1205.
21. Ploemen J.P., Kelder J., Hafmans T., van de Sandt H., van Burgsteden J.A., Saleminki P.J., van Esch E. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp. Toxicol. Pathol. 2004, 55:347-355.
22. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 2006, 5:567-583.
23. Reasor M.J., Kacew S. Drug-induced phospholipidosis: are there functional consequences?. Exp. Biol. Med. (Maywood) 2001, 226:825-830.
24. Sawada H., Takami K., Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 2005, 83:282-292.
25. Sgaragli G.P., Della Corte L., Gremigni D. Chlorimipramine-induced phospholipidosis: biochemical and pharmacokinetic observations in the rat. Pharmacol. Res. Commun. 1983, 15:231-246.
26. Taillardat-Bertschinger A., Martinet C.A., Carrupt P.A., Reist M., Caron G., Fruttero R., Testa B. Molecular factors influencing retention on immobilized artificial membranes (IAM) compared to partitioning in liposomes and n-octanol. Pharm. Res. 2002, 19:729-737.
27. Takashima K., Mizukawa Y., Morishita K., Okuyama M., Kasahara T., Toritsuka N., Miyagishima T., Nagao T., Urushidani T. Effect of the difference in vehicles on gene expression in the rat liver-analysis of the control data in the Toxicogenomics Project Database. Life Sci. 2006, 78:2787-2796.
28. Tengstrand E.A., Miwa G.T., Hsieh F.Y. Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities. Expert Opin. Drug Metab. Toxicol. 2010, 6:555-570.
29. Tomizawa K., Sugano K., Yamada H., Horii I. Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J. Toxicol. Sci. 2006, 31:315-324.
30. Urushidani T., Nagao T. Toxicogenomics: the Japanese initiative. Handbook of Toxicogenomics-Strategies and Applications 2005, 623-631. Wiley-VCH, Weinheim. J. Borak (Ed.).